Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®
Palatin Regains All Rights Company to Receive $16.3 Million from AMAG Teleconference and Webcast to be held on July 27, 2020 Jul 27, 2020, 07:00 ET CRANBURY, N.J., July 27, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin …